Attovia prices upsized Nasdaq IPO

Attovia Therapeutics has set the terms for an upsized U.S. initial public offering, planning to sell 17,000,000 shares at an estimated price of $17.00 per share. Based on these terms, the company is targeting roughly $289 million in gross proceeds from the offering. The upsized structure implies a valuation of about $731.5 million for the biotechnology company.

The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol ATTO. The transaction structure reflects Attovia’s decision to increase the size of its planned listing while maintaining a single estimated price point for investors.

The underwriting syndicate for the IPO includes Morgan Stanley (MS), Leerink Partners, Citigroup and RBC Capital Markets, with LifeSci Capital also listed among the underwriters. These firms will be responsible for marketing the deal to investors and allocating shares at the time of pricing.

An entity affiliated with Goldman Sachs is expected to own about 5.7% of Attovia, based on the company’s filings. This anticipated stake positions the Goldman Sachs–linked investor as a notable shareholder once the IPO is completed.

Attovia was founded in 2023 and operates as a biotechnology company developing biologic therapies. Its research is built around the ATTOBODY platform, which is designed to generate therapeutic candidates for immune-related diseases.

The company’s lead programs target inflammatory skin conditions and inflammatory bowel disease, placing its pipeline within key segments of immunology and inflammatory disorders. These programs are central to Attovia’s strategy as it enters the public markets and seeks capital to advance its biologic candidates.